FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., Ju […]
TOKYO, Jun 9, 2023 – (JC […]
Toyota City, Japan, Jun 9, 202 […]
TOKYO, Jun 9, 2023 – (JC […]
TOKYO, Jun 9, 2023 – (JC […]
TOKYO and CAMBRIDGE, Mass., Ju […]
TOKYO, Jun 7, 2023 – (JC […]
TOKYO, Jun 6, 2023 – (JC […]
TOKYO, Jun 6, 2023 – (JC […]
TOKYO and HAMBURG, June 5, 202 […]
TOKYO, Jun 5, 2023 – (JC […]
TOKYO, Jun 5, 2023 – (JC […]